Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28513626 | 1.00 | CA1 (0.41) | CA1CA2CA12CA9HTT | |
| SCHEMBL27003453 | 1.00 | CA1 (0.41) | CA1CA2CA12CA9HTT | |
| SCHEMBL5116850 | 0.96 | HTT (0.44) | CA1CA2CA12CA9HTT | |
| SCHEMBL5120727 | 0.96 | HTT (0.44) | CA1CA2CA12CA9HTT | |
| SCHEMBL28944441 | 0.96 | CA1 (0.41) | CA1CA2CA12CA9HTT | |
| SCHEMBL28944439 | 0.96 | CA1 (0.41) | CA1CA2CA12CA9HTT | |
| SCHEMBL28779681 | 0.94 | HTT (0.47) | CA1CA2CA12CA9HTT | |
| SCHEMBL3487604 | 0.94 | HTT (0.47) | CA1CA2CA12CA9HTT | |
| SCHEMBL28779725 | 0.91 | HTT (0.47) | CA1CA2CA12CA9HTT | |
| SCHEMBL28779723 | 0.91 | HTT (0.47) | CA1CA2CA12CA9HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015378-A | Small molecule inhibitors of mammalian SLC6A19 function | 杰那医疗公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209656-B1 | INDOLE CARBOXAMIDES COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10604504-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3461821-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9920031-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9802915-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3209656-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-10604504-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | CA1 1518/4885CA2 615/4885CA12 2436/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | CA1 804/4885CA2 168/4885CA12 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.